ANDA 205707, held by Micro Labs Ltd India. Amoxicillin; Clavulanate Potassium.
As of Nov 22, 2026, ANDA 205707 (Amoxicillin and Clavulanate Potassium), held by Micro Labs Ltd India, was first approved by FDA on Dec 30, 2016, with 6 approved supplements and 0 published complete response letters.
Amoxicillin and clavulanate potassium tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 2016 | Original application | Approved | None posted |
| Amoxicillin and Clavulanate Potassium250MG;EQ 125MG BASE · tablet;oral | Amoxicillin; Clavulanate Potassium | Rx |
| Amoxicillin and Clavulanate Potassium500MG;EQ 125MG BASE · tablet;oral | Amoxicillin; Clavulanate Potassium | Rx |
| Dec 11, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 1, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 4, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 4, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 4, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 23, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 30, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters